Company: ZURA
Filing Date: 2025-05-08
Form Type: 10-Q
Source: 0001410578-25-001100
Chunk: 14

Company: Zura Bio Ltd
Filing Date: 2025-05-08
Form: 10-Q
Item: Part I, Item 2M
Chunk 14
---
1b clinical studies have been conducted to date. We are actively assessing the competitive landscape and evaluating potential therapeutic indications for crebankitug.

Torudokimab (ZB-880) is a fully human, high affinity monoclonal antibody that neutralizes interleukin-33 (IL-33), preventing ST2-dependent and ST2-independent (e.g., RAGE) inflammation. The IL-33/ST2 axis stands as a validated therapeutic target for conditions such as chronic obstructive pulmonary disease (“COPD”) and asthma. Three Phase 1/2 clinical studies have been conducted to date. We are continuing to monitor external Phase 2 and Phase 3 IL-33/ST2 data releases from other companies related to asthma and COPD and